Rather than directly attacking the tumor, CPIs harness the power of the endogenous immune system by preventing the exploitation of the immune-evasive mechanisms tumors employ through the CTLA-4 and PD-1/PD-L1 pathways [1,2,3]. Here, CD274 is linked to neoplasm.